2024-10-11 - Analysis Report
## Pfizer Inc. (PFE) Stock Analysis

**1. Performance Comparison with S&P 500 (VOO):**

Pfizer Inc. is a global pharmaceutical company that develops and manufactures medicines and vaccines. The company's stock has underperformed the S&P 500 (VOO) significantly. As of the latest data point, the cumulative return of PFE is -9.69%, while VOO has gained 134.82%, resulting in a **negative divergence of -142.73%.** This divergence indicates that PFE's performance has been much worse than the broader market. The **relative divergence** of 2.32% suggests that the current performance is within the lower percentile of past historical data.

**2. Recent Price Movement:**

* **Closing price:** $30.19
* **5-day moving average:** $29.1
* **20-day moving average:** $29.23
* **60-day moving average:** $29.29

The price is currently trading above the 5-day and 20-day moving averages, but below the 60-day moving average, suggesting **potential short-term bullish momentum**.

**3. Technical Indicators:**

* **RSI:** 55.5 - Indicates the stock is **slightly overbought** but not in extreme territory.
* **PPO:** 0.21 - Suggests potential **short-term upward momentum.**
* **Delta_Previous_Relative_Divergence:** -5.24 - This negative value implies that PFE is **underperforming relative to its recent 20-day trend**. 
* **Expected Return:** 0.0% - Indicates that the estimated 5-year expected return is currently **below the expected return of S&P 500.** 

**4. Recent Earnings & Outlook:**

| Date | EPS | Estimated EPS |
|---|---|---|
| 2024-07-30 | 0.6 | 0.458 |
| 2024-05-01 | 0.82 | 0.516 |
| 2024-01-30 | 0.1 | -0.19 |
| 2023-10-31 | -0.17 | -0.32 |
| 2023-08-01 | 0.67 | 0.56 |

The most recent earnings for the quarter ending July 30th 2024 were $0.6 per share, exceeding the analyst estimate of $0.458. This positive earnings beat suggests that PFE is exceeding expectations in the short term. However, the overall earnings trend exhibits a mix of performance, with some quarters surpassing expectations and others falling short. 

**5. News & Recent Issues:**

**Recent Market Outlook:** Pfizer's stock has been volatile in recent months, influenced by several factors. Investors are keenly watching the company's COVID-19 vaccine and treatment sales, which are expected to decline as the pandemic's intensity wanes. The company's focus on its broader pharmaceutical pipeline, including new cancer treatments and biosimilars, has been a key focus.

**Analyst Opinions:** Analyst opinions on PFE are mixed, with some analysts remaining optimistic about the long-term potential of the company's diverse portfolio, while others are more cautious, citing near-term headwinds from declining COVID-19 revenues.

**Performance Highlights:** PFE has seen some challenges in 2024, with its stock price lagging behind the market. However, the company's robust earnings performance in recent quarters and its continued focus on innovation have provided a foundation for future growth. 

**6. Overall Analysis:**

Pfizer Inc. currently faces headwinds due to declining COVID-19 vaccine sales and an overall market environment that is facing uncertainty. However, the company is well-positioned for long-term growth with its diverse pipeline of potential new drugs. While the stock's recent performance has been disappointing, its positive earnings beat in the most recent quarter offers a glimmer of hope.  Investors should closely monitor Pfizer's financial performance and its new product launches in the coming months to gauge the company's future trajectory. 

**7. Conclusion:**

Pfizer Inc. faces a mixed outlook. While the company's robust earnings beat in the latest quarter provides some optimism, declining COVID-19 revenues and a challenging market environment remain key concerns. Investors should carefully consider these factors before making any investment decisions.
